<DOC>
	<DOCNO>NCT02349113</DOCNO>
	<brief_summary>This study do study age-related bone change woman . The investigator know major cause osteoporosis shortage female hormone estrogen . This study look close shortage estrogen work cause decrease bone formation .</brief_summary>
	<brief_title>Effects Acute Estrogen Therapy Bone Formation</brief_title>
	<detailed_description>Estrogen ( E ) deficiency major cause postmenopausal osteoporosis . Understanding mechanisms E regulate bone metabolism critical develop novel approach prevent treat disorder . We focus define mechanism age-related decrease bone formation role E deficiency mediate decrease . We use novel method develop examine gene expression highly purify bone marrow osteoblastic cell . We test whether increase bone formation previously observe follow acute E treatment woman associate increase marker Wnt/bone morphogenetic protein ( BMP ) signal and/or production othe gene relate bone formation osteoblastic cell .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>At least 10 year postmenopausal ; Menopause define menses least 1 year ( documented ovariectomy ) serum folliclestimulating hormone ( FSH ) 30 IU/L . 1 . Clinically significant abnormality follow screen laboratory study ( review determine PI CI ) : serum 25hydroxyvitamin D ( see ) ; phosphorus ( minor change outside normal guideline acceptable impact study ) ; alkaline phosphatase aspartate transaminase ( AST ) ( minor change outside normal guideline acceptable exceed 50 % normal ineligible ) ; Creatinine ( Cr ) ( minor change outside normal guideline acceptable exceed value 1.2 ineligible ) ; serum calcium must exceed upper limit normal guideline subject ineligible ; FSH need â‰¥30 ; thyroidstimulating hormone ( TSH ) need 0.3 &gt; 10 ; 2 . Presence significant liver disease , renal disease , malignancy ( include breast cancer myeloma ) , malabsorption syndrome , hypoparathyroidism , hyperparathyroidism , acromegaly , Cushing 's syndrome , hypopituitarism , severe chronic obstructive pulmonary disease , untreated gallbladder disease , history myocardial infarction ( MI ) stroke , history thrombophlebitis deep venous thrombosis ; 3 . Undergoing treatment follow drug : adrenocorticoid steroid ( 3 month long anytime &gt; 10 day treatment within previous 12 month ) , anticonvulsant therapy ( within previous year ) , sodium fluoride ( history treatment fluoride ) , pharmacological dos thyroid hormone ( cause decline TSH normal ) , calcium supplementation 1200 mg/d ( within precede 3 month ) , bisphosphonates past , calcitonin ( within past six month ) , E therapy treatment selective estrogen receptor modulator ( within past 6 month ) , parathyroid hormone ( PTH ) use past . Subjects clinical history osteoporotic fracture ( vertebral , hip , distal forearm ) within previous 3 year also exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>estrogen , age</keyword>
</DOC>